{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T21:49:30Z","timestamp":1775339370607,"version":"3.50.1"},"reference-count":72,"publisher":"Frontiers Media SA","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2434,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1111\/j.1432-2277.2008.00771.x","type":"journal-article","created":{"date-parts":[[2008,10,13]],"date-time":"2008-10-13T13:50:26Z","timestamp":1223905826000},"page":"78-89","source":"Crossref","is-referenced-by-count":52,"title":["Calcineurin-inhibitor minimization protocols in heart transplantation"],"prefix":"10.3389","volume":"22","author":[{"given":"Andreas Oliver","family":"Zuckermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arezu Z.","family":"Aliabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","reference":[{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0003-4975(01)02784-9","article-title":"Long-term outcomes after cardiac transplantation: an experience based on different eras of immunosuppressive therapy","volume":"72","author":"John","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.healun.2006.05.002","article-title":"International Society for Heart and Lung Transplantation. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006","volume":"25","author":"Taylor","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1600-6143.2006.01248.x","article-title":"Kidney disease after heart and lung transplantation","volume":"6","author":"Bloom","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB4","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1600-6143.2006.01640.x","article-title":"The outcome of heart transplant recipients following the development of end-stage renal disease: analysis of the Canadian Organ Replacement Register (CORR)","volume":"7","author":"Alam","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0012.2004.00105.x","article-title":"End-stage renal failure and cardiac mortality after heart transplantation","volume":"18","author":"Senechal","year":"2004","journal-title":"Clin Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB7","first-page":"2522","article-title":"Results of immunoconversion from cyclosporine to azathioprine in heart transplant recipients with progressive nephrotoxicity","volume":"19","author":"Hunt","year":"1987","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00007890-199808270-00016","article-title":"A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators","volume":"66","author":"Kobashigawa","year":"1998","journal-title":"Transplantation"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB9","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.0000136812.90177.94","article-title":"Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2\u2003years: a randomized clinical trial","volume":"110","author":"Keogh","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB11","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1600-6143.2006.01290.x","article-title":"Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report","volume":"6","author":"Kobashigawa","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB12","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.healun.2004.08.003","article-title":"Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation","volume":"24","author":"Rosenberg","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB13","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/01.TP.0000130179.18176.3D","article-title":"Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction","volume":"78","author":"Cantarovich","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.healun.2003.09.043","article-title":"Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction","volume":"24","author":"Delgado","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1600-6143.2005.01177.x","article-title":"Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus","volume":"6","author":"Larson","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB16","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of rapamycin inhibitors (sirolimus, and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB17","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1600-6143.2005.00757.x","article-title":"First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation","volume":"1","author":"Meiser","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1432-2277.2005.00258.x","article-title":"Sirolimus in de novo heart transplant recipients with severe renal impairment","volume":"19","author":"Vazquez de Prada","year":"2006","journal-title":"Transpl Int"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB20","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1056\/NEJMoa032953","article-title":"Daclizumab to prevent rejection after cardiac transplantation","volume":"352","author":"Hershberger","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB21","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.healun.2004.09.010","article-title":"A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation","volume":"24","author":"Mehra","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB22","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/00007890-200204150-00030","article-title":"Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor \u201choliday\u201d in solid organ transplant patients with acute renal dysfunction","volume":"73","author":"Cantarovich","year":"2002","journal-title":"Transplantation"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB23","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.healun.2004.10.002","article-title":"Long-term calcineurin inhibitor \u201choliday\u201d using daclizumab in a heart transplant patient with acute renal dysfunction","volume":"24","author":"Potter","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/HCO.0b013e32801466e4","article-title":"Renal protective strategies in heart transplant patients","volume":"22","author":"Cantarovich","year":"2007","journal-title":"Curr Opin Cardiol"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB25","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1097\/00007890-200004270-00012","article-title":"Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine","volume":"69","author":"Aleksic","year":"2000","journal-title":"Transplantation"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB26","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1053-2498(02)00422-9","article-title":"Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil","volume":"21","author":"Tedoriya","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB27","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0041-1345(03)00360-9","article-title":"Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine","volume":"35","author":"Baryalei","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1053-2498(00)00296-5","article-title":"Benefit of mycophenolate-mofetil (MMF) in patients with cyclosporine (CYA) induced nephropathy after cardiac transplantation","volume":"20","author":"Zuckermann","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB29","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1016\/j.transproceed.2004.09.035","article-title":"Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine","volume":"36","author":"Sanchez","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB30","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/01.TP.0000156990.11135.60","article-title":"Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil","volume":"79","author":"Boyer","year":"2005","journal-title":"Transplantation"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1399-0012.2005.00238.x","article-title":"Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule","volume":"19","author":"Manito","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1440-1797.2006.00548.x","article-title":"Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity","volume":"11","author":"Al-Aly","year":"2006","journal-title":"Nephrology"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB33","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.ehj.2004.06.032","article-title":"Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients--the IMPROVED multi-centre study","volume":"25","author":"Angermann","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB34","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.tp.0000253883.52525.7c","article-title":"Mycophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplant patients","volume":"83","author":"Hamour","year":"2007","journal-title":"Transplantation"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB35","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.healun.2007.03.011","article-title":"Low-dose tacrolimus\/sirolimus and steroid withdrawal in heart recipients is highly efficacious","volume":"26","author":"Meiser","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB36","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.healun.2007.02.008","article-title":"Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients","volume":"26","author":"Lehmkuhl","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-2004-820880","article-title":"First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation","volume":"52","author":"Tr\u00f6sch","year":"2004","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.trim.2006.02.001","article-title":"Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients","volume":"16","author":"Schweiger","year":"2006","journal-title":"Transpl Immunol"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB39","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.healun.2006.01.004","article-title":"Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients","volume":"25","author":"Balfour","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.healun.2007.11.565","article-title":"Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients","volume":"27","author":"Ross","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB41","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1016\/j.transproceed.2005.10.005","article-title":"Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure","volume":"37","author":"Lehmkuhl","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.healun.2007.08.014","article-title":"Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation","volume":"27","author":"Zuckermann","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.healun.2007.01.010","article-title":"Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference","volume":"26","author":"Rothenburger","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB44","doi-asserted-by":"crossref","DOI":"10.1097\/00007890-199912270-00003","article-title":"Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients","volume":"68","author":"Cantarovich","year":"1999","journal-title":"Transplantation"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB45","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1399-0012.1998.tb01098.x","article-title":"Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy","volume":"12","author":"Cantarovich","year":"1998","journal-title":"Clin Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB46","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1016\/j.healun.2005.11.251","article-title":"De novo C2 monitoring immediately after cardiac transplantation is not associated with improved renal function","volume":"25","author":"Kittleson","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB47","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1034\/j.1399-0012.2003.00036.x","article-title":"Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction","volume":"17","author":"Cantarovich","year":"2003","journal-title":"Clin Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB48","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.healun.2005.12.005","article-title":"Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation","volume":"25","author":"Barnard","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB49","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/TP.0b013e318169bf43","article-title":"Benefit of neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction","volume":"85","author":"Cantarovich","year":"2008","journal-title":"Transplantation"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB50","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1016\/j.healun.2006.11.417","article-title":"Everolimus in de novo heart transplant recipients six month data on cyclosporine reduction and impact on renal function","volume":"26","author":"Keogh","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB51","doi-asserted-by":"crossref","DOI":"10.1097\/00007890-199912270-00003","article-title":"Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients","volume":"68","author":"Cantarovich","year":"1999","journal-title":"Transplantation"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB52","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.healun.2005.04.019","article-title":"A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients","volume":"24","author":"Mathias","year":"2005","journal-title":"J Heart Lung Transplant"},{"issue":"2S","key":"10.1111\/j.1432-2277.2008.00771.x-BIB53","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1016\/j.healun.2006.11.419","article-title":"Premature Termination of a Prospective, Open Label, Randomized, Multicenter Study of Srl to Replace CNIs (CNI) in a Standard Care Regimen of CNI, MMF and Corticosteroids Early after Heart Transplantation","volume":"26","author":"Hunt","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB54","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1053-2498(01)00421-1","article-title":"Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment","volume":"21","author":"Snell","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB55","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.TP.0000103740.98095.14","article-title":"Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure","volume":"77","author":"Groetzner","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB56","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0041-1345(03)00772-3","article-title":"Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation","volume":"35","author":"Zakliczynski","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB57","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.transproceed.2004.10.062","article-title":"Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation","volume":"36","author":"Lyster","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2006.03.081","article-title":"Switch from cyclosporine to sirolimus as a treatment of acute renal failure complicating cardiogenic shock in a heart transplant recipient","volume":"112","author":"Bestetti","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB59","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1016\/j.transproceed.2005.09.152","article-title":"Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center","volume":"37","author":"Fernandez-Valls","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB60","doi-asserted-by":"crossref","DOI":"10.1016\/j.transproceed.2005.02.090","article-title":"Preservation of renal function after heart transplantation: initial single-center experience with sirolimus","volume":"37","author":"De Meester","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB61","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.transproceed.2006.08.075","article-title":"Sirolimus experience in heart transplantation","volume":"38","author":"Aranda-Dios","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB62","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.transproceed.2005.02.006","article-title":"Sirolimus improves renal function in cardiac transplantation","volume":"37","author":"Cabez\u00f3n","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB63","doi-asserted-by":"crossref","DOI":"10.1016\/j.transproceed.2007.06.048","article-title":"mTor Inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study","volume":"39","author":"Moro","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB64","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.healun.2005.08.015","article-title":"Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity","volume":"24","author":"Kushwaha","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB65","doi-asserted-by":"crossref","DOI":"10.1016\/j.healun.2005.02.018","article-title":"Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation","volume":"24","author":"Hunt","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB66","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1111\/j.1600-6143.2006.01527.x","article-title":"Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy","volume":"6","author":"Gleissner","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB67","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.healun.2007.01.017","article-title":"Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6\u2003months\u2019 follow-up","volume":"26","author":"Rothenburger","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB68","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.healun.2007.07.034","article-title":"Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction","volume":"26","author":"Gustafsson","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB69","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/01.tp.0000276959.56959.69","article-title":"Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients","volume":"84","author":"Raichlin","year":"2007","journal-title":"Transplantation"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB70","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1600-6143.2007.02142.x","article-title":"Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients","volume":"8","author":"Aliabadi","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB71","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/01.CIR.0000070421.38604.2B","article-title":"Use of rapamycin slows progression of cardiac transplantation vasculopathy","volume":"108","author":"Mancini","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1432-2277.2008.00771.x-BIB72","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1161\/CIRCULATIONAHA.107.692996","article-title":"Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation","volume":"116","author":"Raichlin","year":"2007","journal-title":"Circulation"}],"container-title":["Transplant International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1432-2277.2008.00771.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1432-2277.2008.00771.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T18:50:52Z","timestamp":1738435852000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1432-2277.2008.00771.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1432-2277.2008.00771.x","relation":{},"ISSN":["0934-0874","1432-2277"],"issn-type":[{"value":"0934-0874","type":"print"},{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}